|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM34852448X |
| 003 |
DE-627 |
| 005 |
20250304015341.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.cej.2021.134450
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1161.xml
|
| 035 |
|
|
|a (DE-627)NLM34852448X
|
| 035 |
|
|
|a (NLM)36338580
|
| 035 |
|
|
|a (PII)134450
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, Bin
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a V1-Cal hydrogelation enhances its effects on ventricular remodeling reduction and cardiac function improvement post myocardial infarction
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 08.11.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status PubMed-not-MEDLINE
|
| 520 |
|
|
|a Myocardial infarction (MI) is a major cause of disability and mortality worldwide. A cell permeable peptide V1-Cal has shown remarkable therapeutic effects on ML However, using V1-Cal to improve long-term cardiac function after MI is presently limited by its short half-life. Herein, we co-assembled V1-Cal with a well-known hydrogelator Nap-Phe-Phe-Tyr (NapFFY) to obtain a new supramolecular hydrogel V1-Cal/NapFFY. We found that the hydrogel could significantly enhance the therapeutic effects of V1-Cal on ventricular remodeling reduction and cardiac function improvement in a myocardial infarction rat model. In vitro experiments indicated that co-assembly of V1-Cal with NapFFY significantly increased mechanic strength of the hydrogel, enabling a sustained release of V1-Cal for more than two weeks. In vivo experiments supported that sustained release of V1-Cal from V1-Cal/NapFFY hydrogel could effectively decrease the expression and activation of TRPV1, reduce apoptosis and the release of inflammatory factors in a MI rat model. In particular, V1-Cal/NapFFY hydrogel significantly decreased infarct size and fibrosis, while improved cardiac function 28 days post MI. We anticipate that V1-Cal/NapFFY hydrogel could be used clinically to treat MI in the near future
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Myocardial infarction
|
| 650 |
|
4 |
|a Supramolecular hydrogel
|
| 650 |
|
4 |
|a Sustained release
|
| 650 |
|
4 |
|a TRPV1
|
| 650 |
|
4 |
|a V1-Cal
|
| 700 |
1 |
|
|a Wu, Chengfan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a He, Shufang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Yaguang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Di
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tao, Hui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Chenchen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pang, Xiaoxi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Fei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yuan, Yue
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gross, Eric R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liang, Gaolin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Ye
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Chemical engineering journal (Lausanne, Switzerland : 1996)
|d 1999
|g 433(2022), Pt 1 vom: 01. Apr.
|w (DE-627)NLM098273531
|x 1385-8947
|7 nnas
|
| 773 |
1 |
8 |
|g volume:433
|g year:2022
|g number:Pt 1
|g day:01
|g month:04
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.cej.2021.134450
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 433
|j 2022
|e Pt 1
|b 01
|c 04
|